Argonaute RNA

Mike as CEO leads Argonaute in all scientific aspects. He blends deep siRNA domain knowledge with clinical experience and has taken siRNA drugs through IND to design and completion of Phase 2. He is the former CMO of Silence Therapeutics plc, and has over 25 years of experience as a leader in R&D, spanning the full spectrum of preclinical, translational and clinical development. Mike was a Clinical Lecturer in Medicine at UCLH and former Head of Molecular Medicine and Associate Professor of Medicine at the University of Warwick. He is a senior clinician leading one of the foremost cardio metabolic clinics in the UK, based at the University Hospitals of Coventry and Warwickshire NHS Trust. He is an expert advisor to NICE and the EC, and has contributed to establishing the current state of the art for treatment and prevention of cardiovascular diseases in the UK.